Gut Microbiota-Based Therapies for Irritable Bowel Syndrome | Zendy

E Stern | Zendy; Darren M. Brenner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Gut Microbiota-Based Therapies for Irritable Bowel Syndrome

Author(s) -

E Stern,

Darren M. Brenner

Publication year - 2018

Publication title -

clinical and translational gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.673

H-Index - 35

ISSN - 2155-384X

DOI - 10.1038/ctg.2018.2

Subject(s) - irritable bowel syndrome , medicine , gut flora , rifaximin , diarrhea , constipation , antibiotics , abdominal pain , gastroenterology , small intestinal bacterial overgrowth , immunology , microbiology and biotechnology , biology

Irritable bowel syndrome (IBS) is a common, heterogeneous disorder characterized by abdominal pain associated with changes in bowel habits. The pathogenesis of IBS is multifactorial and may relate to alterations in the gut microbiota, changes in visceral sensation and motility, and genetic and environmental factors. Administration of systemic antibiotics may increase the risk of IBS by altering gastrointestinal homeostasis. Therapeutic interventions for IBS with diarrhea that are thought to target alterations in the gut microbiota include the nonsystemic antibiotic rifaximin, the medical food serum-derived bovine immunoglobulin, prebiotics, probiotics, and dietary modification. SYN-010 is a modified-release statin formulation that reduces methane production by Methanobrevibacter smithii and is currently in development for the treatment of patients with constipation-predominant IBS. Use of these interventions in the management of patients with IBS may function to restore a healthy gut microbiota and ameliorate symptoms of IBS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research